Drug-induced morphea: Report of a case induced by balicatib and review of the literature

Journal of the American Academy of Dermatology

Volumn 59, Issue 1, 2008, Pages 125-129

  Peroni, Anna ^a   Zini, Antonio ^a   Braga, Vania ^a   Colato, Chiara ^a   Adami, Silvano ^a   Girolomoni, Giampiero ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BALICATIB; CALCIUM CARBONATE; COLECALCIFEROL; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; STEROID;

ADULT; CASE REPORT; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MORPHEA; MULTICENTER STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REMISSION; REVIEW; SKIN BIOPSY; TREATMENT DURATION;

ADMINISTRATION, ORAL; BENZAMIDES; CATHEPSINS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCLERODERMA, LOCALIZED;

EID: 45049083216     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.03.009     Document Type: Review

References (32)

1. Vasoo S. Drug-induced lupus: an update. Lupus 15 (2006) 757-761
2. Dourmishev A.L., and Dourmishev L.A. Dermatomyositis and drugs. Adv Exp Med Biol 455 (1999) 187-191
3. Haustein U.F., and Haupt B. Drug-induced scleroderma and sclerodermiform conditions. Clin Dermatol 16 (1998) 353-366
4. Peak A.S., and Sheller A. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis. Ann Pharmacother 41 (2007) 1481-1485
5. Gilmour T.K., Wilkinson B., Breit S.N., and Kossard S. Analysis of dendritic cell populations using a revised histological staging of morphea. Br J Dermatol 143 (2000) 1183-1192
6. De Dobbeler G., Engelholm J.L., and Heenen M. Morphea after beta-blocker therapy. Eur J Dermatol 3 (1993) 108-109
7. Cohen I.S., Mosher M.B., O'Keefe E.J., Klaus S.N., and De Conti R.C. Cutaneous toxicity of bleomycin therapy. Arch Dermatol 107 (1973) 553-555
8. Bork K., and Korting G.W. Symptomatische Sklerodermie durch bleomyzin. Hautarzt 34 (1983) 10-12
9. Kim K.H., Yoon T.J., Oh C.W., Ko G.H., and Kim T.H. A case of bleomycin-induced scleroderma. J Korean Med Sci 11 (1996) 454-456
10. Asano Y., Ihn H., Shikada J., Kadono T., Kikuchi K., and Tamaki K. A case of peplomycin-induced scleroderma. Br J Dermatol 150 (2004) 1213-1214
11. Bernstein R.M., Hall M.A., and Gostelow B.E. Morphea-like reaction to D-penicillamine therapy. Ann Rheum Dis 40 (1981) 42-44
12. Liddle B.J. Development of morphoea in rheumatoid arthritis treated with penicillamine. Ann Rheum Dis 48 (1989) 963-964
13. Leshin B., Piette W.W., and Caplan R.M. Morphea after bromocriptine therapy. Int J Dermatol 28 (1989) 177-179
14. Auffranc J.C., Berbis J.F., Fabre J.F., Garnier J.P., and Privat Y. Syndrome sclérodermiforme et poïkilodermique observé au cours d'un traitement par carbidopa et 5-hydroxy-tryptophanne. Ann Dermatol Venereol 112 (1985) 691-692
15. Lampert A., Joly P., Thomine E., Ortoli J.C., and Lauret P. Syndrome sclérodermiforme à type de morphées bulleuses au cours d'un traitement par 5-hydroxy-tryptophane, carbidopa et flunitrazepam. Ann Dermatol Venereol 119 (1992) 209-211
16. Bellman B., and Berman B. Localized indurated brown plaques on arms and right buttock. Arch Dermatol 132 (1996) 1366-1367 1368-9
17. Ho J., Rothchild Y.H., and Sengelmann R. Vitamin B12-associated localized scleroderma and its treatment. Dermatol Surg 30 (2004) 1252-1255
18. Giudetti M.S., Vincenzi C., Papi M., and Tosti A. Sclerodermatous skin reaction after vitamin K1 injections. Contact Dermatitis 31 (1994) 45-46
19. Morell A., Betlloch I., Sevila A., Bañulus J., and Rotella R. Morphea-like reaction from vitamin K1. Int J Dermatol 34 (1995) 201-202
20. Alonso-Llamazares J., and Ahmed I. Vitamin K1-induced localized scleroderma (morphea) with linear deposition of IgA in the basement membrane zone. J Am Acad Dermatol 38 (1998) 322-324
21. Kvernmo T., Härtter S., and Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 28 (2006) 1065-1078
22. Vasiljeva O., Reinheckel T., Peters C., Turk D., Turk V., and Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 13 (2007) 385-401
23. Yasuda Y., Kaleta J., and Bromme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 57 (2005) 973-993
24. Lecaille F., Kaleta J., and Bromme D. Human and parasitic papain-like cysteine proteases : their role in physiology and pathology and recent developments in inhibitor design. Chem Rev 102 (2002) 4459-4488
25. Potts W., Bowyer J., Jones H., Ticker D., Freemont A.J., Millest A., et al. Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy. Int J Exp Pathol 85 (2004) 85-96
26. Rünger T.M., Quintanilla-Dieck M.J., and Bhawan J. Role of cathepsin K in the turnover of the dermal extracellular matrix during scar formation. J Invest Dermatol 127 (2007) 293-297
27. Rieman D.J., McClung H.A., Dodds R.A., Hwang S.M., Lark M.W., Holmes S., et al. Biosynthesis and processing of cathepsin K in cultured human osteoclasts. Bone 28 (2001) 282-289
28. Bossard M.J., Tomaszek T.A., Thompson S.K., Amegadzie B.Y., Hanning C.R., Jones C., et al. Proteolytic activity of human osteoclasts cathepsin K. J Biol Chem 271 (1996) 12517-12524
29. Deaton D.N., and Tavares F.X. Design of cathepsin K inhibitors for osteoporosis. Curr Top Med Chem 5 (2005) 1639-1675
30. Desmarais S., Black W.C., Oballa R., Lamontagne S., Riendeau D., Tawa P., et al. Effect of cathepsin k inhibitor basicity on in vivo off-target activities. Mol Pharmacol 73 (2007) 147-156 Epub 2007 Oct 16
31. Khalfan H.A. Study of thiol proteases of normal human skin fibroblasts. Cell Biochem Funct 9 (1991) 55-62
32. Bühling F., Röcken C., Brasch F., Hartig R., Yasuda Y., Saftig P., et al. Pivotal role of cathepsin K in lung fibrosis. Am J Pathol 164 (2004) 2203-2216